Clinical Trials Browser

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Gallbladder Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07334119 2026-02-19

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Phase 1 Recruiting

60 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT01196390 2026-02-18

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Phase 3 Completed

203 enrolled 22 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT07182149 2026-02-12

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Phase 1 Recruiting

150 enrolled

BreastGastrointestinalGynecologicHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06623396 2026-02-11

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

Phase 1 Recruiting

18 enrolled

BreastGastrointestinalGynecologic

Adenocarcinoma Of Esophagus, Breast Neoplasms, Diabetes Mellitus, Peritoneal Neoplasms

NCT07392892 2026-02-06

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

Phase 2/3 Not yet recruiting

840 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06560645 2026-02-02

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Phase 1 Terminated

42 enrolled

GastrointestinalThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07375420 2026-02-02

OPTIMUS

Phase NA Recruiting

50 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Motor Activity

NCT04290806 2026-01-28

SAPHIR

Recruiting

1,900 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasms

NCT06266299 2026-01-28

A Study of KK2269 in Adult Participants With Solid Tumors

Phase 1 Recruiting

101 enrolled

GastrointestinalThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03961945 2026-01-26

Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

Phase NA Recruiting

1,550 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus, Esophageal Neoplasms, Gastroesophageal Reflux

NCT07206589 2026-01-23

Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial

Phase NA Not yet recruiting

1,010 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT07277413 2026-01-20

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Phase 1 Recruiting

260 enrolled

GastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Mesothelioma, Neoplasm Metastasis, Recurrence

NCT07284186 2026-01-16

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

155 enrolled

GastrointestinalThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT07343869 2026-01-15

FEO

Not yet recruiting

750 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

NCT07212491 2025-12-31

Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma

Enrolling by invitation

300 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

NCT07309991 2025-12-30

Impact of Arterial Partial Pressure of Oxygen on Anastomotic Leakage After Esophagectomy

Completed

2,083 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT05945823 2025-12-29

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

Phase 2 Active not recruiting

53 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT06161818 2025-12-22

TNT-OES-2

Phase 2 Recruiting

216 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT07059299 2025-12-19

NeoTISLEGA

Phase 1 Recruiting

18 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06549816 2025-12-15

A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

Phase 1 Completed

6 enrolled

GastrointestinalGynecologicHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT06532734 2025-12-10

Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype

Recruiting

25 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Rumination Syndrome, Anorexia Nervosa, Feeding and Eating Disorders, Barrett Esophagus, Bulimia, Vomiting

NCT07090499 2025-12-09

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Phase 1 Recruiting

310 enrolled

GastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Pancreatic Neoplasms

NCT07260734 2025-12-03

AROMA2

Not yet recruiting

6,000 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT06251973 2025-12-02

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Phase 2 Recruiting

37 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

Phase 1 Active not recruiting

120 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Phase 1 Terminated

50 enrolled

GastrointestinalGynecologicSarcoma

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06846346 2025-11-28

GRACIE

Phase 2 Recruiting

88 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Neoplasms

NCT01142388 2025-11-25

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Phase 2 Active not recruiting

94 enrolled 8 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06687603 2025-11-13

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

Phase NA Recruiting

800 enrolled

Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus, Gastroesophageal Reflux

Clinical Trials

Obeticholic Acid for Prevention in Barrett's Esophagus

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

ablation IN BE

STAR-221

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

OLIGOMETS

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

HERIZON-GEA-01

EDGE-Gastric

TroFuse-015

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Endeavor-1

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

OPTIMUS

SAPHIR

A Study of KK2269 in Adult Participants With Solid Tumors

Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

Minimally Invasive Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Cancer, SOS5C Trial

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

FEO

Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma

Impact of Arterial Partial Pressure of Oxygen on Anastomotic Leakage After Esophagectomy

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

TNT-OES-2

NeoTISLEGA

A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

Barrett's Esophagitis in Anorexia Nervosa Binge/Purge Subtype

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

AROMA2

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

(VELA) Study of BLU-222 in Advanced Solid Tumors

GRACIE

Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms